News
Zacks.com on MSN6d
CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?
CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.
University of Pennsylvania is suing three leading insulin makers and companies that negotiate drug price deals for insurance plans, accusing them of a scheme to drive up prices of a medication that ...
" PA is an independent, nonpartisan, and nonprofit newsroom producing investigative and public-service journalism that holds ...
The perk is worth up to $31,412.40 a year for lawmakers choosing a top-tier family plan, but not everyone takes it.
In this opinion piece, former Democratic National Committee chairperson Howard Dean urges Democrats in Congress to help lower ...
The big health insurers Moody's rates now face shrinking profit margins at the Medicaid plans they manage for state ...
Act 624 of 2025 bans pharmacy benefit managers (PBMs) from holding a permit to operate a drug store in Arkansas after Jan. 1, ...
Zacks Investment Research on MSN1d
CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?
CVS Health Corporation CVS is scheduled to report second-quarter 2025 results on July 31, before the opening bell. In the ...
A federal judge said Wednesday that he will decide “fairly soon” whether to block Arkansas’ first-in-the-nation law regulating pharmacy benefit managers (PBMs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback